# Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab

> **NCT03306446** · PHASE4 · UNKNOWN · sponsor: **Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives** · enrollment: 203 (actual)

## Conditions studied

- CD

## Interventions

- **DRUG:** Start adalimumab in monotherapy

## Key facts

- **NCT ID:** NCT03306446
- **Lead sponsor:** Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03-17
- **Primary completion:** 2021-03
- **Final completion:** 2025-03
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03306446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03306446, "Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03306446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*